KALV Stock Earnings: KalVista Pharma Misses EPS for Q4 2024 KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the fourth quarter of 2024.
Insiders Buying Dorian LPG And 2 Other Stocks Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
What's Going With Hereditary Angioedema-Focused KalVista Pharmaceuticals Stock On Tuesday? Results from KalVista Pharmaceuticals' Phase 3 KONFIDENT trial. Sebetralstat, an oral on-demand therapy, shows efficacy for hereditary angioedema.
Insiders Buying Monro And 3 Other Stocks Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
$230M Bet On Talos Energy? Check Out These 4 Stocks Insiders Are Buying Although U.S. stocks closed higher on Friday, there were a few notable insider trades.
Insiders Buying KalVista Pharmaceuticals And 3 Other Stocks Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.
$6.5M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying Although U.S. stocks closed slightly higher on Friday, there were a few notable insider trades.
KALV Stock Earnings: KalVista Pharma Misses EPS for Q2 2024 KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the second quarter of 2024.
3 Micro-Cap Stocks That Could Be Moonshots If you are hungry for high-risk returns, then these micro-cap stocks to buy could be your winning ticket to future yields.
